07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Ritter management update

Ritter Pharmaceuticals Inc. , Los Angeles. Calif.   Business: Gastrointestinal   Hired: Robert Tidwell as CBO, formerly SVP of corporate development at Cell Genesys Inc. , which merged with BioSante Pharmaceuticals Inc.  ...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Pathwork Diagnostics management update

Pathwork Diagnostics Inc. , Redwood City, Calif.   Business: Diagnostic   Hired: Sharon Tetlow as CFO, formerly SVP and CFO of Cell Genesys Inc. , which merged with BioSante Pharmaceuticals Inc.  ...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

GVAX Prostate cancer vaccine: Development restarted

BioSante said FDA lifted a clinical hold on the GVAX Prostate cancer vaccine to treat prostate cancer after additional data analyses addressed side effect concerns. BioSante is planning to begin a Phase II trial of...
00:20 , Jun 7, 2011 |  BC Extra  |  Clinical News

FDA lifts hold on BioSante vaccine

FDA lifted a clinical hold on GVAX Prostate Cancer vaccine from BioSante Pharmaceuticals Inc. (NASDAQ:BPAX). The company said the hold was lifted after additional data analyses addressed side-effect concerns. BioSante is planning to begin a...
07:00 , May 23, 2011 |  BioCentury  |  Strategy

Takeda's global boost

Acquiring Nycomed will transform Takeda Pharmaceutical Co. Ltd. into a complete global pharma company by combining geographically complementary marketing operations. But the Japanese pharma will need more acquisitions to get its market cap back to...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

BioSante, Cold Genesys deal

Cold Genesys received exclusive, worldwide rights to develop and commercialize BioSante's oncolytic virus technology, including CG0070 . BioSante received a 19.9% ownership of Cold Genesys, a $95,000 upfront payment and is eligible to receive milestones...
07:00 , May 27, 2010 |  BC Innovations  |  Targets & Mechanisms

Coaxing cancer to defect

The immune system has a hard time attacking tumors because malignant cells do not express potent antigens that could elicit a strong immune response. Whereas most cancer vaccine strategies attempt to boost the body's response...
07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

GVAX vaccine for prostate cancer: Development restarted

BioSante restarted development of GVAX immunotherapy to treat prostate cancer and expects to begin a Phase II trial in 4Q10. The company said it is taking steps to lift the clinical hold on the program,...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Company News

Biogen Idec biopharmaceuticals news

Biogen Idec appointed Eric Rowinsky and Stephen Sherwin to its board as part of a deal in which Carl Icahn agreed to support the company's slate of directors at the upcoming annual meeting. Icahn had...